Mast cells positive to tryptase and tumour-associated macrophages correlate with angiogenesis in locally advanced colorectal cancer patients undergone to surgery

Expert Opinion on Therapeutic Targets

Volumn 20, Issue 5, 2016, Pages 533-540

  Ammendola, Michele ^a,b   Patruno, Rosa ^b   Sacco, Rosario ^a   Marech, Ilaria ^b   Sammarco, Giuseppe ^a   Zuccalà, Valeria ^a   Luposella, Maria ^a   Zizzo, Nicola ^c   Gadaleta, Claudia ^b   Porcelli, Mariangela ^b   Gadaleta, Cosmo Damiano ^b   Ribatti, Domenico ^d,e   Ranieri, Girolamo ^b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b NATIONAL CANCER CENTRE   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^e NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Angiogenesis; Colorectal cancer; Macrophages; Mast cells; Tryptase

Indexed keywords

TRYPTASE;

ADULT; ADVANCED CANCER; ARTICLE; CARCINOGENESIS; CELL DENSITY; CELL INFILTRATION; CELL STRUCTURE; CLINICAL FEATURE; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MALE; MAST CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; COLORECTAL TUMOR; MACROPHAGE; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

COLORECTAL NEOPLASMS; FEMALE; HUMANS; MACROPHAGES; MALE; MAST CELLS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; TRYPTASES;

EID: 84961200255     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2016.1158811     Document Type: Article

References (67)

1. Malvezzi M, Bertuccio P, Levi F, et al. European cancer mortality predictions for the year 2012. Ann Oncol. 2012; 23 (4): 1044-1052. doi: 10.1093/annonc/mds024. [PMID: 22373539].
2. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005; 23 (15): 3502-3508. doi: 10.1200/JCO.2005.10.017. [PMID: 15908660].
3. Midgley R, Kerr D. Colorectal cancer. Lancet. 1999; 353 (9150): 391-399. doi: 10.1016/S0140-6736(98)07127-X. [PMID: 9950460].
4. Tanaka T, Ishikawa H. Mast cells and inflammation-associated colorectal carcinogenesis. Semin Immunopathol. 2013; 35 (2): 245-254. doi: 10.1007/s00281-012-0343-7. [PMID: 22993030].
5. Khan MW, Keshavarzian A, Gounaris E, et al. PI3K/AKT signaling is essential for communication between tissue-infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancer. Clin Cancer Res. 2013; 19 (9): 2342-2354. doi: 10.1158/1078-0432.CCR-12-2623. [PMID: 23487439 PMCID: 3947836].
6. Kawada M, Seno H, Kanda K, et al. Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene. 2012; 31 (26): 3111-3123. doi: 10.1038/onc.2011.498. [PMID: 22056877 PMCID: 3290745].
7. Irani AM, Schwartz LB. Human mast cell heterogeneity. Allergy Proc. 1994; 15 (6): 303-308. [PMID: 7721078].
8. Marshall JS. Mast-cell responses to pathogens. Nat Reviews Immunol. 2004; 4 (10): 787-799. doi: 10.1038/nri1460. [PMID: 15459670].
9. Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology. 2007; 74 (2): 121-132. doi: 10.1159/000101711. [PMID: 17587883].
10. Ribatti D, Guidolin D, Marzullo A, et al. Mast cells and angiogenesis in gastric carcinoma. Int J Exp Pathol. 2010; 91 (4): 350-356. doi: 10.1111/j.1365-2613.2010.00714.x. [PMID: 20412338 PMCID: 2962893].
11. Marech I, Ammendola M, Gadaleta C, et al. Possible biological and translational significance of mast cells density in colorectal cancer. World J Gastroenterol. 2014; 20 (27): 8910-8920. doi: 10.3748/wjg.v20.i27.8910. [PMID: 25083063 PMCID: 4112891].
12. Marech I, Ammendola M, Sacco R, et al. Serum tryptase, mast cells positive to tryptase and microvascular density evaluation in early breast cancer patients: possible translational significance. BMC Cancer. 2014; 14: 534. doi: 10.1186/1471-2407-14-534. [PMID: 25056597 PMCID: 4117953].
13. Marech I, Gadaleta CD, Ranieri G. Possible prognostic and therapeutic significance of c-Kit expression, mast cell count and microvessel density in renal cell carcinoma. Int J Mol Sci. 2014; 15 (7): 13060-13076. doi: 10.3390/ijms150713060. [PMID: 25056544 PMCID: 4139891].
14. Ammendola M, Sacco R, Sammarco G, et al. Correlation between serum tryptase, mast cells positive to tryptase and microvascular density in colo-rectal cancer patients: possible biological-clinical significance. PLoS One. 2014; 9 (6): e99512. doi: 10.1371/journal.pone.0099512. [PMID: 24915568 PMCID: 4051753].
15. Ammendola M, Sacco R, Sammarco G, et al. Mast cells density positive to tryptase correlates with angiogenesis in pancreatic ductal adenocarcinoma patients having undergone surgery. Gastroenterol Res Pract. 2014; 2014: 951957. doi: 10.1155/2014/951957. [PMID: 24995015 PMCID: 4065688].
16. Patruno R, Marech I, Zizzo N, et al. c-Kit expression, angiogenesis, and grading in canine mast cell tumour: a unique model to study c-Kit driven human malignancies. Biomed Res Int. 2014; 2014: 1-8. doi: 10.1155/2014/730246. [PMID: 24900982 PMCID: 4036613].
17. Ranieri G, Passantino L, Patruno R, et al. The dog mast cell tumour as a model to study the relationship between angiogenesis, mast cell density and tumour malignancy. Oncol Rep. 2003; 10 (5): 1189-1193. [PMID: 12883679].
18. Ranieri G, Patruno R, Lionetti A, et al. Endothelial area and microvascular density in a canine non-Hodgkins lymphoma: an interspecies model of tumor angiogenesis. Leuk Lymphoma. 2005; 46 (11): 1639-1643. doi: 10.1080/10428190500205150. [PMID: 16236617].
19. Ammendola M, Zuccalà V, Patruno R, et al. Tryptase-positive mast cells and angiogenesis in keloids: a new possible post-surgical target for prevention. Updates Surg. 2013; 65 (1): 53-57. doi: 10.1007/s13304-012-0183-y. [PMID: 23117746].
20. Gulubova M, Vlaykova T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J Gastroenterol Hepatol. 2009; 24 (7): 1265-1275. doi: 10.1111/j.1440-1746.2007.05009.x. [PMID: 17645466].
21. Zizzo N, Patruno R, Zito FA, et al. Vascular endothelial growth factor concentrations from platelets correlate with tumor angiogenesis and grading in a spontaneous canine non-Hodgkin lymphoma model. Leuk Lymphoma. 2010; 51 (2): 291-296. doi: 10.3109/10428190903452818. [PMID: 20001231].
22. Ranieri G, Labriola A, Achille G, et al. Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma. Int J Oncol. 2002; 21 (6): 1317-1323. [PMID: 12429983].
23. Khatami M. Chronic inflammation: synergistic interactions of recruiting macrophages (TAMs) and eosinophils (Eos) with host mast cells (MCs) and tumorigenesis in CALTs. M-CSF, suitable biomarker for cancer diagnosis! Cancers. 2014; 6 (1): 297-322. doi: 10.3390/cancers6010297. [PMID: 24473090 PMCID: 3980605].
24. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature. 2004; 431 (7007): 405-406. doi: 10.1038/431405a. [PMID: 15385993].
25. Fukata M, Chen A, Vamadevan AS, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology. 2007; 133 (6): 1869-1881. doi: 10.1053/j.gastro.2007.09.008. [PMID: 18054559 PMCID: 2180834].
26. Li Q, Withoff S, Verma IM. Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol. 2005; 26 (6): 318-325. doi: 10.1016/j.it.2005.04.003. [PMID: 15922948].
27. Ranieri G. Hot topic: targeting tumor angiogenesis: an update. Curr Med Chem. 2012; 19 (7): 937. [PMID: 22214460].
28. Khazaie K, Blatner NR, Khan MW, et al. The significant role of mast cells in cancer. Cancer Metastasis Rev. 2011; 30 (1): 45-60. doi: 10.1007/s10555-011-9286-z. [PMID: 21287360].
29. Ranieri G, Grammatica L, Patruno R, et al. A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients. J Cell Mol Med. 2007; 11 (2): 362-368. doi: 10.1111/j.1582-4934.2007.00007.x. [PMID: 17378915 PMCID: 3822834].
30. Ribatti D, Ranieri G, Basile A, et al. Tumor endothelial markers as a target in cancer. Expert Opin Ther Targets. 2012; 16 (12): 1215-1225. doi: 10.1517/14728222.2012.725047. [PMID: 22978444].
31. Blair RJ, Meng H, Marchese MJ, et al. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest. 1997; 99 (11): 2691-2700. doi: 10.1172/JCI119458]. [PMID: 9169499 PMCID: 508115].
32. Ribatti D, Ranieri G, Nico B, et al. Tryptase and chymase are angiogenic in vivo in the chorioallantoic membrane assay. Int J Dev Biol. 2011; 55 (1): 99-102. doi: 10.1387/ijdb.103138dr. [PMID: 21425085].
33. Malfettone A, Silvestris N, Saponaro C, et al. High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression. J Cell Mol Med. 2013; 17 (8): 1025-1037. doi: 10.1111/jcmm.12073. [PMID: 23991686 PMCID: 3780541].
34. Hassan S, Kinoshita Y, Kawanami C, et al. Expression of protooncogene c-kit and its ligand stem cell factor (SCF) in gastric carcinoma cell lines. Dig Dis Sci. 1998; 43 (1): 8-14. [PMID: 9508539].
35. Caronni N, Savino B, Bonecchi R. Myeloid cells in cancer-related inflammation. Immunobiology. 2015; 220 (2): 249-253. doi: 10.1016/j.imbio.2014.10.001. [PMID: 25454487].
36. Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front Immunol. 2014; 5: 614. doi: 10.3389/fimmu.2014.00614. [PMID: 25506346 PMCID: 4246889].
37. Gosselin D, Link VM, Romanoski CE, et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell. 2014; 159 (6): 1327-1340. doi: 10.1016/j.cell.2014.11.023. [PMID: 25480297 PMCID: 4364385].
38. Sunderkötter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukoc Biol. 1994; 55 (3): 410-422. [PMID: 7509844].
39. Chanmee T, Ontong P, Konno K, et al. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers. 2014; 6 (3): 1670-1690. doi: 10.3390/cancers6031670. [PMID: 25125485 PMCID: 4190561].
40. Polverini PJ, Leibovich SJ. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Investig. 1984; 51 (6): 635-642. [PMID: 6209469].
41. Polverini PJ. How the extracellular matrix and macrophages contribute to angiogenesis-dependent diseases. Eur J Cancer. 1996; 32A (14): 2430-2437. [PMID: 9059331].
42. Mantovani A. Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. Lab Investig. 1994; 71 (1): 5-16. [PMID: 7518882].
43. Canna K, McArdle PA, McMillan DC, et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2005; 92: 651-654.
44. Garlipp B, Ptok H, Schmidt U, et al. Factors influencing the quality of total mesorectal excision. Br J Surg. 2012; 99 (5): 714-720. doi: 10.1002/bjs.8692. [PMID: 22311576].
45. Khan JS, Hemandas AK, Flashman KG, et al. Clinical outcome of laparoscopic and open colectomy for right colonic carcinoma. Ann R Coll Surg Engl. 2011; 93 (8): 603-607. doi: 10.1308/147870811X13137608455299. [PMID: 22041236 PMCID: 3566685].
46. Nakashima M, Akiyoshi T, Ueno M, et al. Colon cancer in the splenic flexure: comparison of short-term outcomes of laparoscopic and open colectomy. Surg Laparosc Endosc Percutan Tech. 2011; 21 (6): 415-418. doi: 10.1097/SLE.0b013e31823aca96. [PMID: 22146163].
47. Astler VB, Coller FA. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg. 1954; 139 (6): 846-852. [PMID: 13159135 PMCID: 1609522].
48. Ratto C, Ricci R. Potential pitfalls concerning colorectal cancer classification in the seventh edition of the AJCC cancer staging manual. Dis Colon Rectum. 2011; 54 (8): e232. doi: 10.1097/DCR.0b013e31821def52. [PMID: 21730773].
49. Su Y, Lin Y, Zhang L, et al. CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer. Cancer Sci. 2014; 105 (1): 26-34. doi: 10.1111/cas.12304. [PMID: 24131472].
50. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992; 3 (2): 65-71. [PMID: 1378311].
51. Pimentel-Nunes P, Goncalves N, Boal-Carvalho I, et al. Decreased Toll-interacting protein and peroxisome proliferator-activated receptor gamma are associated with increased expression of Toll-like receptors in colon carcinogenesis. J Clin Pathol. 2012; 65 (4): 302-308. doi: 10.1136/jclinpath-2011-200567. [PMID: 22228906].
52. Furuta T, Imajo-Ohmi S, Fukuda H, et al. Mast cell-mediated immune responses through IgE antibody and Toll-like receptor 4 by malarial peroxiredoxin. Eur J Immunol. 2008; 38 (5): 1341-1350. doi: 10.1002/eji.200738059. [PMID: 18398934].
53. Zorn CN, Keck S, Hendriks RW, et al. Brutons tyrosine kinase is dispensable for the Toll-like receptor-mediated activation of mast cells. Cell Signal. 2009; 21 (1): 79-86. doi: 10.1016/j.cellsig.2008.09.010. [PMID: 18848985].
54. He W, Liu Q, Wang L, et al. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 2007; 44 (11): 2850-2859. doi: 10.1016/j.molimm.2007.01.022. [PMID: 17328955].
55. Wolska A, Lech-Marańda E, Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett. 2009; 14 (2): 248-272. doi: 10.2478/s11658-008-0048-z. [PMID: 19096763].
56. Sideris M, Papagrigoriadis S. Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer. Anticancer Res. 2014; 34 (5): 2061-2068. [PMID: 24778007].
57. Coppedè F, Lopomo A, Spisni R, et al. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol. 2014; 20 (4): 943-956. doi: 10.3748/wjg.v20.i4.943. [PMID: 24574767 PMCID: 3921546].
58. Marech I, Patruno R, Zizzo N, et al. Masitinib (AB1010), from canine tumor model to human clinical development: where we are? Crit Rev Oncol Hematol. 2014; 91 (1): 98-111. doi: 10.1016/j.critrevonc.2013.12.011. [PMID: 24405856].
59. Leporini C, Patanè M, Saullo F, et al. A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations. BioDrugs: Clin Immunotherapeutics, Biopharm Gene Ther. 2014; 28 (6): 499-511. doi: 10.1007/s40259-014-0100-7. [PMID: 25209722].
60. Ammendola M, Leporini C, Marech I, et al. Targeting mast cells tryptase in tumor microenvironment: a potential antiangiogenetic strategy. Biomed Res Int. 2014; 2014: 154702. doi: 10.1155/2014/154702. [PMID: 25295247 PMCID: 4177740].
61. Ribatti D, Ranieri G. Tryptase, a novel angiogenic factor stored in mast cell granules. Exp Cell Res. 2015; 332 (2): 157-162. doi: 10.1016/j.yexcr.2014.11.014. [PMID: 25478999].
62. Ribatti D. Mast cells as therapeutic target in cancer. Eur J Pharmacol; 2015. doi: 10.1016/j.ejphar.2015.02.056. [PMID: 25917325].
63. Caughey GH. Mast cell proteases as pharmacological targets. Eur J Pharmacol; 2015. doi: 10.1016/j.ejphar.2015.04.045. [PMID: 25958181].
64. Shiff SJ, Koutsos MI, Qiao L, et al. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res. 1996; 222 (1): 179-188.
65. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012; 13 (5): 518-527.
66. Flossmann E, Rothwell PM. British doctors aspirin trial and the UK-TIA aspirin trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007; 369 (9573): 1603-1613.
67. Yang YH, Yang YH, Cheng CL, et al. The role of chemoprevention by selective cyclooxygenase-2 inhibitors in colorectal cancer patients-a population-based study. BMC Cancer. 2012; 12: 582.